Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. lessened its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 7.0% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,577 shares of the company’s stock after selling 119 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Medpace were worth $649,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Signaturefd LLC raised its holdings in shares of Medpace by 4.9% during the second quarter. Signaturefd LLC now owns 559 shares of the company’s stock valued at $230,000 after acquiring an additional 26 shares during the last quarter. Commonwealth Equity Services LLC raised its stake in Medpace by 0.7% in the 2nd quarter. Commonwealth Equity Services LLC now owns 4,340 shares of the company’s stock valued at $1,787,000 after purchasing an additional 32 shares during the last quarter. Benjamin F. Edwards & Company Inc. lifted its holdings in Medpace by 5.3% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 781 shares of the company’s stock valued at $316,000 after purchasing an additional 39 shares in the last quarter. Journey Advisory Group LLC boosted its stake in Medpace by 1.9% during the 2nd quarter. Journey Advisory Group LLC now owns 2,390 shares of the company’s stock worth $984,000 after purchasing an additional 44 shares during the last quarter. Finally, Coldstream Capital Management Inc. grew its holdings in shares of Medpace by 5.0% during the fourth quarter. Coldstream Capital Management Inc. now owns 954 shares of the company’s stock worth $292,000 after buying an additional 45 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Up 1.4 %

Shares of Medpace stock opened at $356.69 on Tuesday. Medpace Holdings, Inc. has a 52-week low of $227.21 and a 52-week high of $459.77. The company has a market capitalization of $11.06 billion, a P/E ratio of 36.36, a P/E/G ratio of 1.74 and a beta of 1.35. The company has a 50 day moving average of $383.30 and a 200 day moving average of $393.01.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, July 22nd. The company reported $2.75 EPS for the quarter, topping analysts’ consensus estimates of $2.54 by $0.21. Medpace had a net margin of 16.74% and a return on equity of 55.14%. The firm had revenue of $528.10 million during the quarter, compared to the consensus estimate of $528.41 million. During the same quarter in the previous year, the firm posted $1.93 earnings per share. The company’s revenue was up 14.6% compared to the same quarter last year. As a group, research analysts anticipate that Medpace Holdings, Inc. will post 11.66 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. StockNews.com upgraded Medpace from a “hold” rating to a “buy” rating in a research report on Thursday, September 5th. William Blair reissued an “outperform” rating on shares of Medpace in a research report on Wednesday, September 11th. Truist Financial began coverage on shares of Medpace in a research report on Thursday, August 1st. They set a “hold” rating and a $415.00 price objective for the company. Guggenheim decreased their target price on shares of Medpace from $464.00 to $432.00 and set a “buy” rating on the stock in a report on Wednesday, July 24th. Finally, TD Cowen cut their price target on shares of Medpace from $452.00 to $434.00 and set a “buy” rating for the company in a report on Wednesday, July 24th. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $423.00.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.